Physician profile
Aaron Thomas
NPI 1902997885
$970.79
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2021: $167 · 2022: $108 · 2023: $40.81 · 2024: $13.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $178.09 | 2021-2022 | |
| Pfizer INC. | $164.46 | 2019-2021 | |
| Lilly USA, LLC | $99.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $93.01 | 2019 | |
| Novo Nordisk INC | $64.87 | 2019-2024 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.55 | 2019 | |
| Merck Sharp & Dohme LLC | $42.79 | 2019 | |
| Astellas Pharma US INC | $41.23 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.37 | 2019 | |
| Abbott Laboratories | $32.20 | 2019 | |
| Genentech USA, INC. | $26.69 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.59 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.77 | 2023 | Jynarque |
| Amgen INC. | $18.70 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.08 | 2019 | |
| Glaxosmithkline, LLC. | $14.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.74 | 2019 | |
| Allergan, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.